- Home
- NAC vs NRIX Comparison
NAC vs NRIX Comparison
Compare NAC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAC | NRIX |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAC | NRIX |
|---|---|---|
| Price | $11.80 | $17.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 712.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $10.52 | $8.20 |
| 52 Week High | $12.25 | $22.50 |
Technical Indicators
Market Signals| Indicator | NAC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 59.28 |
| Support Level | $11.78 | $16.81 |
| Resistance Level | $12.05 | $19.98 |
| Average True Range (ATR) | 0.11 | 0.91 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 94.05 | 76.12 |
Price Performance
Historical ComparisonAbout NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.